Abecma, Breyanzi, CARVYKTI, Kymriah, Tecartus, Yeskarta
Human-Based CAR T Cell Therapy: Breakthroughs and Challenges
Introduction In the domain of oncology, immunotherapy has emerged as a pioneering methodology, harnessing the body's immune system to combat malignant tumors. There are many immunotherapeutic approaches, but Chimeric Antigen Rece..
Brexucabtagene autoleucel, European Union, Gilead, Kite, Tecartus
Tecartus granted European marketing authorization for treatment of relapsed or refractory acute lymphoblastic leukemia
Sept 2022: The European Commission (EC) has authorized Kite's CAR T-cell therapy Tecartus® (brexucabtagene autoleucel) for the treatment of adult patients 26 years of age and older with relapsed or refractory (r/r) B-cell precurs..
BALL, Brexucabtagene autoleucel, Kite Pharma, Tecartus, ZUMA-3
Brexucabtagene autoleucel is approved by FDA for relapsed or refractory B-cell precursor acute lymphoblastic leukemia
October 2021: Brexucabtagene autoleucel (Tecartus, Kite Pharma, Inc.) has been approved by the Food and Drug Administration for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). In..
Acalabrutunib, Avelumab, CART therapy, Dabrafanib, Kymriah, Latest drugs, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Latest drugs in the treatment of cancer
July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..